期刊文献+

他汀类药物的多效性及对糖代谢的影响 被引量:13

The pleiotropic effects and impact on glucose metabolism of statins
下载PDF
导出
摘要 他汀类药物应用于高脂血症患者及心脑血管疾病的一二级预防,越来越多的研究表明,他汀类在降脂、抗炎、保护血管内皮、稳定动脉粥样硬化斑块、抗心律失常同时,还会影响患者的血糖水平。因此,全面了解他汀类药物的作用,指导临床用药意义重大。 Statins are applied in the patients with hyperlipidemia and in the cardiovascular and cerebrovascular diseases primary and secondary prevention.More and more studies indicate that statins not only reduce blood lipid,have antiinflammatory action,protect the vascular endothelium,but also affect glucose level.Therefore,comprehensive understanding of the role of statins help guide the clinical treatment.
出处 《安徽医药》 CAS 2013年第1期11-14,共4页 Anhui Medical and Pharmaceutical Journal
关键词 他汀类 降脂 血糖 statins blood lipid reduction glucose level
  • 相关文献

参考文献29

  • 1Alagona P Jr.Pitavastatin:evidence for its place in treatment of hypercholesterolemia[R].Core Evidence,2010:91-105.
  • 2Grundy SM.Consensus statement:role of therapy with "statin" in patients with hypertriglyceridemia[J].Am J Cardiol,1998,81(4):1B-6B.
  • 3Corsini A.The Safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk[J].Cardiovascular Drugs and Theraphy,2003,17(3):265-285.
  • 4Reilly T,Pharm D,King G,et al.Pitavastatin for Hyperlipidemia And Mixed Dyslipidemia[J].Drug Forecast,2010,35(4):197.
  • 5Marais AD,Naoumova RP,Firth JC,et al.Decreased production of low density lipoprotein by atrovastain after apheresis in homozygous familial hypercholesterolemia[J].Atherosclerosis J Lipid Res,1997,38(10):2071-2078.
  • 6Raal FJ,Pilcher GJ,Pappu AS,et al.Expanded-dose Simvastain is effective in homozygous familial hypercholeslerolemia[J].Atherosclerosis,1997,135(2):249-256.
  • 7Jones PH,Davidson MH,Stein EA,et al.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin,simvastatin,and pravastatin across doses[J].Am J Cardiol,2003,92(2):152-160.
  • 8Yoshitomi Y,lshii T,Kaneki M,et al.Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia:results of a 12 week,open label study[J].J Atheroscler Thromb,2006,13(2):108-113.
  • 9荆珊,孙宁玲,王鸿懿,卢熙宁.匹伐他汀钙片治疗原发性高胆固醇血症疗效和安全性[J].中国新药杂志,2008,17(9):775-777. 被引量:15
  • 10McKenney JM,Farnier M,LoK W,et al.Safety and efficiency of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia[J].J Am Coll Cardiol,2006,47(8):1584-1587.

二级参考文献29

  • 1商丽华,胡大一,赵秀丽,张仁汉.普伐他汀对快速起搏心房肌结构重构的影响[J].中华心律失常学杂志,2004,8(3):172-176. 被引量:21
  • 2张繁之,王琳,张存泰,卜军,陈斌.阿托伐他汀对肥厚心肌缝隙连接重构的影响[J].中国现代医学杂志,2006,16(8):1145-1148. 被引量:5
  • 3HAYASHI T, AROCKIA J, FUKATSU A, et al. A new HMGCoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits[ J ]. Atherosclerosis, 2004, 176(2) :255 - 263.
  • 4SHITARA Y, SUGIYAMA Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions[J]. Pharmacol Ther, 2006, 112(1): 71-105.
  • 5SAITO Y, YAMADA N, TERAMOTO T, et al. Clinical efficacy of pitavastatin, a new of 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitor, in patients with hyperlipidemia[ J]. Arzneimittelforsch, 2002, 52(4) :251 - 255.
  • 6SAITO Y, YAMADA N, TERAMOTO T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin verus pravastatin in patients with primary hypercholesterolemia [J]. Atheroslerosis, 2002, 162(2) :373 -379.
  • 7Siu C W, Lau C P, Tse H F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion[ J]. Am J Cardiol,2003, 92 ( 11 ) : 1343-1345.
  • 8Young X Y ,Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease [ J ]. Am J Cardiol, 2003,92 ( 12 ) : 1379-1383.
  • 9Ozaydin M,Varol E,Aslan S M,et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical eardioversion[ J ]. Am J Cardiol,2006,97 ( 10 ) : 1490-1493.
  • 10Hanna I R, Heeke B, Bush H, et al. The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction [ J]. J Am Coil Cardiol, 2006,47 ( 8 ) : 1683-1688.

共引文献18

同被引文献138

  • 1石桂艳,王晓威.超说明书用药现状分析[J].求医问药(下半月),2013(7):34-35. 被引量:6
  • 2张玉蓉,吕卓人.调脂治疗理念转变的思考[J].中华心血管病杂志,2006,34(8):760-761. 被引量:16
  • 3刘军锋,贾克刚,刘运德.基质金属蛋白酶与心脏重构及心肌病理损害的研究进展[J].中华老年心脑血管病杂志,2007,9(7):499-500. 被引量:12
  • 4于扬,李建平,霍勇.早发冠心病危险因素和冠状动脉病变特点的研究[J].中国介入心脏病学杂志,2007,15(5):270-273. 被引量:15
  • 5Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorv- astatin on LDL and HDL particle concentrations in patients with metabolic syndrome : a randomized, double-blind, controlled study [J]. Diabetes Care,2009,32(6) :1087-1091.
  • 6Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus [ J ]. Eur Heart J, 2005,26 ( 21 ) : 2224- 2231.
  • 7Koh KK. Effects of statins on vascular wall:vasomotor function, inflammation, and plaque stability [ J ]. Cardiovasc Res, 2000,47 (4) :648-657.
  • 8Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy[ J]. N Engl J Med,2005,352 ( 1 ) :20-28.
  • 9Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease [ J ]. N Engl J Med,2005,352( 1 ) :29-38.
  • 10He J,Gu D,Wu X,et al.Major cause of death among men and women in China[J].N Engl J Med,2005,353(11):1124-1134.

引证文献13

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部